Key Points {#FPar1}
==========

This study represents the first study of rapid-acting intranasal insulin in the Down syndrome populationIntranasal insulin was safe and well tolerated in Down syndromeAdditional studies are necessary to evaluate the efficacy of rapid-acting insulin in Down syndrome

Introduction {#Sec1}
============

Down syndrome (DS) is the most common chromosomal anomaly recognized at birth, with an incidence of about 1 in 1000 births in the USA \[[@CR1]\]. Down syndrome is caused by the presence of all or part of an extra copy of chromosome 21, which can lead to developmental delay along with cognitive impairment \[[@CR2]\].

The majority of individuals with DS are likely to develop clinical and neuropathological brain changes resembling Alzheimer's dementia (AD) by the ages of 35--40 years, which include deposits of extracellular amyloid-beta oligomers, intracellular neurofibrillary tangles, and cerebral glucose hypometabolism \[[@CR3]--[@CR5]\]. Whereas cholinesterase inhibitors and memantine are US Food and Drug Administration-approved medications for AD, there are no existing treatment options for cognitive impairment in DS.

Insulin regulates the pathological hallmark proteins associated with both AD and DS, including neurofibrillary tangles and amyloid plaques \[[@CR6]--[@CR8]\]. Increasing central insulin levels may decrease neurofibrillary tangle formation through inhibition of tau phosphorylation by maintaining the phosphorylation equilibrium between kinase and phosphatase activity \[[@CR9]\]. Insulin reduces amyloid plaque burden through the stimulation of the insulin degrading enzyme \[[@CR10]\]. Finally, insulin receptor signaling increases synaptic density, which may counteract the characteristic loss of synapses occurring in AD and DS \[[@CR11]\]. The numerous neuropathological similarities that exist in AD and DS characterize the insulin signaling pathway as a promising treatment approach in DS.

Intranasal (IN) insulin has been studied in mild cognitive impairment and AD, showing benefits on verbal retrieval performance in as little as 15 min of a single administration \[[@CR7]\] as well as lasting for as long as 4 months \[[@CR12]\]. One potential mechanism for the rapid effects on cognition may relate to the effect of insulin on cerebral glucose metabolism; studies have shown that low doses of insulin increase cerebral glucose metabolism in the cortex \[[@CR7], [@CR13]\]. Furthermore, studies have suggested that rapid-acting (RA) insulins may have greater effects on memory than regular insulin \[[@CR14]\].

For this investigation, we used glulisine, an RA insulin analog lacking the zinc-containing compounds typically found in other insulin formulations that have the potential to cause olfactory neuron toxicity \[[@CR15], [@CR16]\]. Furthermore, we employed a novel nasal delivery device known as the Impel NeuroPharma I109 Precision Olfactory Delivery (POD^®^) device.

In the current study, we were interested in demonstrating the safety and tolerability of IN RA insulin glulisine in subjects with DS. We had a secondary objective of measuring the effect of IN RA insulin glulisine on cognition and memory.

Materials and Methods {#Sec2}
=====================

This 8-week single-center study (ClinicalTrials.gov ID NCT02432716) enrolled 12 adult subjects with DS aged 35--80 years. All subjects either had prior karyotyping or underwent karyotyping through the study to confirm the diagnosis.

Study eligibility was determined by a neurological evaluation (cranial nerves motor examination, coordination, sensation, reflexes, and gait), medical history, physical examination, electrocardiogram, and laboratory studies. Patients were excluded for any history of additional psychiatric or neurologic diagnoses expected to impact cognition beside DS, history of drug or alcohol abuse, status of residing in a skilled nursing facility, presence of seizure disorder, Hachinski score \> 4, history of diabetes mellitus or insulin use, history of insulin intolerance, recent exposure within 30 days to an experimental drug for DS, and inability to comply with the protocol for treatment. Any participants with a neuropsychiatric index-C aggression or agitation subscore \> 4 (severity \> 2; frequency \> 2) were excluded from the trial. If screening laboratory studies showed glycosylated hemoglobin \> 6.1%, patients were prohibited from participating in the investigation (refer to Table 1 of the Electronic Supplementary Material \[ESM\] for full inclusion and exclusion criteria).

The design was a phase II, double-blinded, placebo-controlled, randomized cross-over study. Randomization was stratified by sex a priori by the permuted block method. One clinician at the site was unblinded to randomization and prepared the study dose for each subject. This person did not have responsibility for obtaining study data. The investigators were provided with a sealed envelope containing the true sequence of glulisine and saline for each group if the blind needed to be broken because of unforeseen circumstances.

All subjects underwent a screening visit where fasting laboratory samples for basic metabolic panel, glucose, and insulin levels were drawn. During this visit, a test dose of IN saline was delivered to ensure subjects tolerated the nasal delivery device. Subjects were then randomized using a 1:1 allocation ratio to initially receive either IN glulisine 20 IU or placebo (Fig. [1](#Fig1){ref-type="fig"}). This dose was based on that used in our prior IN glulisine study in mild-moderate AD \[[@CR17]\]. The study dose was administered within the clinical setting by the primary investigator at two separate visits with a 7- to 24-day washout period between visits. Subjects initially assigned to glulisine later received placebo during the subsequent visit at least 1 week later, and vice versa. A total of 0.20 mM of glulisine or placebo was administered using the POD^®^ device to deliver 0.10 mL of agent in each nostril for a total of 20 IU. Subjects were seated during the administration.Fig. 1Study design

Twenty minutes after receiving the IN treatment, subjects were administered a cognitive battery consisting of the Rivermead Behavioral Memory Test (RBMT) \[[@CR18]\] and Fuld Object Memory Evaluation (FOME) \[[@CR19]\] under the supervision of a licensed fellowship-trained neuropsychologist. These tests were chosen based on their relevance to cognitive impairment in the DS population and for purposes of minimizing floor effects. This investigation was not powered to detect changes on cognitive assessment and, thus, these batteries were administered for the purpose of feasibility rather than efficacy.

For safety assessment, all subjects underwent completion of vital signs, a physical examination, and a neurological examination at each research visit. A finger-stick glucose level was obtained at the start of each treatment visit and 30 min post-administration. Serum insulin levels, a basic metabolic panel, and glucose levels were obtained during the baseline visit and post-treatment for all subjects. A final safety visit in which subjects completed vital signs, a general/neurological examination, and laboratory studies was scheduled 7--24 days after the second treatment visit.

Baseline patient characteristics across randomized groups were compared using t-tests and Fisher's exact tests. Treatment effects on both primary and secondary endpoints were assessed using common statistical methodology for AB/BA crossover designed trials. We planned to test the occurrence of adverse events using a mixed-effects Poisson regression model accounting for period effect, the treatment-period interaction, subject age, and sex. Cognitive outcomes from the FOME and RBMT were tested between glulisine and saline periods using two-sided two-sample t-tests. Both treatment and period differences were assessed for these analyses; although period effects were expected to be non-significant owing to the balanced nature of our design. Vitals and laboratory values were summarized by visit and a change in these values were compared for glulisine and saline periods using paired two-sample t-tests. All statistical analyses were conducted in SAS Version 9.4. The study was performed in accordance with the Declaration of Helsinki and the protocol was approved by the Regions Hospital Institutional Review Board under protocol \#14-105. All participants and their caregivers provided written informed consent prior to inclusion into the study.

Results {#Sec3}
=======

The participants consisted of six female and six male individuals with a mean age of 42.7 years (range 35--53 years) (Table [1](#Tab1){ref-type="table"}). All subjects were Caucasian. Nine subjects had completed high school (75%), two subjects had completed college (16.7%), and data were missing for a single subject (8.3%). The mean baseline glycosylated hemoglobin was 5.4. The randomized groups had similar baseline characteristics for age, sex, ethnicity, education, and glycosylated hemoglobin.Table 1Baseline demographics of the study populationStudy population (*N* = 12)Age42.7 (1.7)Male6 (50%)White12 (100%)Education High school9 (75%) College2 (16.7%) Missing1 (8.3%)Glycosylated hemoglobin5.4 (0.1)Values listed as mean (standard error) or *n* (%)

All subjects tolerated the test IN saline dose. Safety data for vital signs were missing for a single participant in the post-saline group. There were no adverse events or serious adverse events reported by any participating subjects. Given the lack of adverse events, we were unable to perform the planned mixed-effects Poisson regression analysis; however, this outcome indicates the treatment was well tolerated among our sample. Vital signs showed a significant increase in systolic blood pressure compared to baseline with glulisine as compared with placebo (Table [2](#Tab2){ref-type="table"}). Otherwise, there were no significant effects of glulisine relative to placebo on heart rate, respirations, temperature, O~2~ saturation, or peripheral glucose. There were no significant differences between post-glulisine and post-placebo groups compared to baseline for serum glucose and insulin levels.Table 2Comparison of change in vitals and blood glucose during glulisine and placebo visitsSaline (*N* = 11)Glulisine (*N* = 12)*P* valueChange in vitals SBP− 7.8 (3.5)0.9 (3.2)0.010 DBP− 2.1 (3.8)5.1 (2.6)0.230 Pulse− 3.4 (2.7)− 0.8 (2.7)0.246 Respirations0.2 (0.2)− 0.2 (0.2)0.163 Temperature0.1 (0.1)0.2 (0.1)0.436 O~2~ saturation− 0.3 (0.6)− 0.8 (0.4)0.438Laboratory tests Glucose99.7 (4.5)95.0 (4.7)0.222 Insulin level10.9 (2.1)12.4 (2.6)0.740Values listed as mean (standard error)*DBP* diastolic blood pressure, *SBP* systolic blood pressure

On the FOME, there was no significant impact of IN glulisine on learning, immediate recall, delayed recall, memory retention, recognition memory, and retention estimate (Table [3](#Tab3){ref-type="table"}). On the RBMT, there was significantly improved immediate recall in the post-placebo group compared with the post-glulisine group. Furthermore, a trend toward improved performance on memory retention (*p* = 0.067) was found in the post-glulisine group compared with the post-saline group. Otherwise, no significant difference was found between treatment and placebo groups for delayed recall and memory recognition (refer to Table [2](#Tab2){ref-type="table"} of the ESM for performance at individual visits).Table 3Comparison of cognitive outcomes post-saline and post-glulisine periodsPost-saline (*N* = 12)Post-glulisine (*N* = 12)*P* valueFOME Learning curve (0--10)2.3 (0.5)2.0 (0.6)0.634 Total immediate recall (0--50)33.8 (3.5)36.8 (3.3)0.089 Total delayed recall (0--10)6.1 (0.6)6.4 (0.8)0.388 Memory retention (0--100)72.3 (5.3)68.7 (6.5)0.669 Recognition memory (0--10)2.3 (0.3)1.9 (0.5)0.414 Retention estimate (0--10)8.3 (0.4)8.3 (0.6)1.000RBMT Immediate recall (0--31)6.6 (1.4)5.4 (1.2)0.035 Delayed recall (0--31)6.6 (1.5)7.2 (1.4)0.512 Memory retention (0--100)9.7 (1.3)16.9 (3.8)0.067Values listed as mean (standard error)RBMT memory retention is missing for one subject at the post-saline visit*FOME* Fuld Object Memory Evaluation, *RBMT* Rivermead Behavioral Memory Test

Discussion {#Sec4}
==========

We showed that a single dose of IN glulisine was safe and well tolerated in this patient population. Similar to past IN clinical trials, our investigation confirmed the lack of an impact of IN insulin in the central nervous system on peripheral glucose levels, suggesting that this safety outcome may not require close monitoring in future IN insulin clinical trials. Although prior studies have demonstrated that the effects of IN insulin include elevated blood pressures \[[@CR20]\], we did not find any evidence for clinically significant hypertension. Systolic blood pressure was increased with glulisine compared with placebo, but there was no elevation of blood pressures into the clinically significant range. There was concern among the investigators that subjects with DS as a result of their developmental delay would be unable to tolerate the insertion of the Impel POD^®^ device into the nares; our experience showed this population was not oppositional to the IN route of drug delivery.

This pilot study was not powered to detect the effect of IN glulisine on cognitive performance in subjects with DS. There was a non-significant trend toward improved memory retention in the post-glulisine group on the RBMT, warranting further investigation of IN glulisine on this outcome variable. Factors to be considered in future studies to determine clinical efficacy should consider the daily dose of IN insulin as well as the longitudinal duration of treatment. The IN glulisine dose used in our single-dose cross-over clinical trial (20 IU) is lower than the daily dose of 40 IU administered in more extensive randomized, double-blind, placebo-controlled studies in mild cognitive impairment and AD \[[@CR12]\]. The FOME and RBMS were appropriate cognitive batteries to assess outcomes in this patient population, lacking either a ceiling or floor effect.

The strengths of this study include the fact that all subjects with DS were confirmed using chromosomal analysis. The investigation used an IN device designed specifically to target the upper one-third of the nasal sinus for brain-nose delivery. Finally, this study is the first to our knowledge to explore the role of insulin for cognitive impairment in patients with DS.

Limitations of this study include the relatively small number of participating subjects, which impacted the ability to demonstrate clinical efficacy with the employed neuropsychometric measures. In addition, this trial evaluated outcomes in the setting of a single dose, and whether longitudinal administration of IN RA insulin is safe and well tolerated remains in question. Finally, the study was limited by a lack of diversity with a cohort that was 100% Caucasian.

Conclusions {#Sec5}
===========

Intranasal RA insulin was safe and well tolerated in the DS population. Considering the lack of available therapeutic interventions for cognitive decline in DS, as well as the potential impact on cerebral amyloid plaques, further efficacy trials of IN insulin in DS are warranted to better understand the relationship between IN insulin and cognition in this population.
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